Main Uses of Entyvio

Entyvio (vedolizumab) is a biologic medication specifically designed to treat two chronic inflammatory bowel diseases (IBD). It is used when conventional therapies or other specialized treatments have not provided an adequate response, have stopped working, or are not tolerated by the patient.

Ulcerative Colitis

Entyvio is indicated for the treatment of adult patients with moderate to severe active ulcerative colitis. This condition causes inflammation and ulcers in the lining of the large intestine (colon) and rectum. The medication works to reduce this inflammation, helping to manage symptoms and improve the condition of the intestinal lining.

Crohn’s Disease

Entyvio is used for adult patients with moderate to severe active Crohn’s disease. Crohn’s disease is a chronic condition that causes inflammation anywhere along the digestive tract, though it most commonly affects the small intestine and the beginning of the large intestine. The treatment aims to control the inflammatory process that leads to the symptoms of the disease.

Benefits and Goals of Treatment

The primary objective of using Entyvio is to help patients achieve and maintain control over their symptoms through several clinical stages:

• Inducing Remission: Reducing active inflammation to bring the disease into a quiet state where symptoms are significantly diminished or absent.
• Maintaining Remission: Sustaining the inactive state of the disease over the long term to prevent flare-ups.
• Improving Mucosal Healing: Promoting the actual healing of the intestinal lining, which can be observed during medical examinations.
• Reducing Steroid Dependency: Helping patients decrease or eliminate their reliance on corticosteroids, which are often used for short-term symptom control but are not ideal for long-term use due to side effects.

Mechanism of Action

Entyvio is a gut-selective integrin receptor antagonist. Unlike some other biologic treatments that affect the entire immune system, Entyvio specifically targets the movement of white blood cells into the digestive tract. By blocking certain proteins on the surface of these cells, it prevents them from entering the inflamed gut tissues, thereby reducing the localized inflammation characteristic of ulcerative colitis and Crohn’s disease.

Who Can and Cannot Use Entyvio (Vedolizumab)?

Entyvio is a prescription medication used to treat moderately to severely active Ulcerative Colitis (UC) and Crohn’s Disease (CD) in adults when certain other treatments haven't worked well enough or can't be tolerated. It may be used to help achieve and maintain remission and to promote mucosal healing.

Who Can Use Entyvio?

Entyvio is typically used for patients who meet the following general criteria:

• Adults (18 years and older) with moderately to severely active UC or CD.
• Those who have had an inadequate response, lost response to, or are intolerant to one or more conventional therapies (like corticosteroids, immunomodulators) or a tumor necrosis factor (TNF) blocker.

Who Cannot Use Entyvio?

Entyvio is contraindicated (should not be used) in patients with a known history of a severe hypersensitivity reaction to vedolizumab or any of its excipients. Additionally, caution is generally advised, and the decision is made on a case-by-case basis by a healthcare provider, for individuals with:

• Active, severe infections (e.g., tuberculosis, sepsis, cytomegalovirus).
• A history of or current Progressive Multifocal Leukoencephalopathy (PML), though a causal link has not been established.

Before starting Entyvio, a thorough medical history and assessment are necessary to ensure the treatment is safe and appropriate for the individual patient.

Interactions with other medicines and products

The official interaction profile for Entyvio (vedolizumab) is structured around mandatory restrictions and timing rules due to its specific immunomodulatory effects, rather than common metabolic interactions. All documented restrictions are based strictly on governmental regulatory information.

The co-administration of Natalizumab (Tysabri) is formally not recommended in official documents due to the potential for an increased risk of Progressive Multifocal Leukoencephalopathy (PML). For patients previously exposed to Natalizumab, a minimum 12-week wash-out period is a required timing constraint before initiating vedolizumab therapy.

Restrictions on Immunizations and Other Biologics

Administration of live or oral vaccines is restricted during therapy. Regulatory guidance mandates that patients should be brought up to date with all necessary immunizations according to current guidelines prior to initiating vedolizumab treatment. Caution or avoidance is also advised for the concurrent use of other targeted biologics, such as TNF blockers, as this combination has the potential for additive immunosuppressive effects.

Vedolizumab is a monoclonal antibody and is not metabolized via the cytochrome P450 (CYP) enzyme system. The regulatory profile confirms that co-administered corticosteroids and conventional immunomodulators (such as azathioprine or methotrexate) do not significantly alter the exposure of vedolizumab. Furthermore, no specific interactions are documented with food, alcohol, or herbal products.

Энтивио (vedolizumab) operates through a selective antagonism mechanism by binding with high affinity to the alpha4beta7 integrin surface protein expressed on circulating memory T lymphocytes and other leukocytes. This molecular blockade inhibits the interaction between alpha4beta7 and its endothelial ligand, MAdCAM-1, which is constitutively expressed on blood vessels within the gastrointestinal tract. This mechanistic cascade prevents the crucial step of immune cell extravasation (migration) from the bloodstream into the intestinal tissue. The resulting restriction of immune cell homing is highly selective to the gut, avoiding inhibition of immune cell trafficking in non-GI organs. By limiting the influx of pro-inflammatory immune cells, the drug significantly reduces the local immune burden within the intestinal wall. This physiological shift lowers the concentration of localized inflammatory mediators and modulates processes related to epithelial integrity. The localized reduction of immune cell influx limits the progression of chronic inflammation within the affected intestinal tissue.

Administration and Dosing Guidelines

Энтивио (vedolizumab) is administered by intravenous (IV) infusion or subcutaneous (SC) injection, strictly following a healthcare provider's instructions. The regimen begins with an Intravenous (IV) Induction phase.

Dosing Schedule for Adults

IV Infusion Procedure:

• The 300 mg lyophilized powder must be reconstituted with 4.8 mL of sterile water for injection and then diluted in 250 mL of 0.9% sodium chloride or Lactated Ringer's solution.
• The infusion should be administered slowly over approximately 30 minutes. Patients must be monitored during and for a period after the IV infusion.

SC Injection Procedure:

• The pre-filled syringe or pen should be allowed to warm to room temperature for about 30 minutes before use.
• The injection is administered into the thigh, abdomen, or upper arm, with the site rotated for each dose.

Missed Dose Instructions:

• If an IV maintenance dose is missed, it should be given as soon as possible, and the 8-week schedule should be resumed from that date.
• If an SC dose is missed, it should be injected as soon as possible, and the 2-week schedule should be resumed from that date.

All administration must be performed by or under the guidance of a healthcare professional. Therapy should be discontinued if no evidence of therapeutic benefit is observed by a specified point in treatment (e.g., Week 14 for Crohn's disease).

Энтивио (Vedolizumab): Recent Clinical Evidence

The clinical profile of vedolizumab is primarily supported by results from the GEMINI Phase 3 trial program in adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). These studies evaluated the ability of the drug to induce and maintain clinical response and remission.

Ulcerative Colitis (UC) Findings

• Response and Remission: In the GEMINI I trial, a statistically significant portion of participants with UC achieved clinical response as early as Week 6, and maintained clinical remission at Week 52 compared to those on placebo.
• Steroid-Free Remission: Study results also indicated that a greater percentage of vedolizumab-treated patients who were using corticosteroids at the start of the study achieved corticosteroid-free clinical remission at one year compared to placebo.
• Head-to-Head Comparison: The VARSITY study, a head-to-head trial against adalimumab, demonstrated that vedolizumab was associated with significantly higher rates of clinical remission and mucosal healing at Week 52 in patients with moderately to severely active UC.

Crohn's Disease (CD) Findings

• Remission Rates: In the GEMINI II trial, a statistically significant greater proportion of patients achieved clinical remission at Week 52 compared to the placebo group. The benefit was observed both in patients who had failed prior anti-TNF therapy and those who had not.
• Subcutaneous Administration: The VISIBLE 2 trial specifically investigated the subcutaneous (SC) formulation for maintenance therapy in CD, demonstrating that patients on vedolizumab SC achieved significantly greater rates of long-term clinical remission at Week 52 compared to placebo. This supports the availability of both intravenous (IV) and subcutaneous administration for maintenance treatment.

Common questions about Энтивио (FAQ)

Q: How is Энтивио different from general TNF blockers?

A: According to official documentation, Entyvio has a gut-selective mechanism of action. This means it is designed to target inflammation primarily in the intestinal tract, which may result in less systemic immune activity compared to non-selective biologics like TNF blockers. The official product information advises caution regarding concurrent use with TNF blockers due to the potential for increased infection risk.

Q: Is Энтивио intended for long-term treatment?

A: Official treatment guidelines indicate that Entyvio is intended for both inducing (starting) and maintaining clinical response and remission. The dosing regimen is structured with an initial induction phase followed by an ongoing maintenance phase. Continued use is generally assessed periodically by a healthcare provider to ensure therapeutic benefit is being maintained.

Q: Are the side effects of Энтивио generally considered severe?

A: Regulatory documents classify side effects by how often they occur. While most common side effects are generally non-serious (such as headache or common cold symptoms), the official product information lists Serious Adverse Reactions. These include the possibility of Serious Infections (like Sepsis), Progressive Multifocal Leukoencephalopathy (PML), and Liver Injury.

Q: What types of infections are commonly monitored for while on Энтивио treatment?

A: Official safety restrictions state that treatment should not be started in patients who have active, severe infections, such as tuberculosis (TB), sepsis, or cytomegalovirus, until these conditions are controlled. Regulatory guidance also indicates that patients should be current on all necessary immunizations prior to initiating treatment.

Q: What is reported about the long-term safety data for Энтивио in clinical studies?

A: Long-term safety has been assessed in clinical studies and extension trials. The product information documents all known adverse reactions, categorized by frequency, based on the data observed across the total patient experience, including long-term use.

Q: What kinds of medical tests are usually required before a person can start taking Энтивио?

A: Before starting treatment, a thorough medical assessment is required to confirm that the patient does not have any active, severe infections. Official guidance also indicates that patients should be current on necessary immunizations prior to starting therapy, which often implies specific screening tests.

Q: Is it possible for the effectiveness of Энтивио to decrease over time?

A: Yes, regulatory documentation acknowledges that some patients may experience a decrease in therapeutic response during the maintenance phase. The official prescribing information notes that a change in the intravenous dosing frequency may be considered by the healthcare provider to help regain effectiveness.

Q: What percentage of patients achieved remission in the key research studies for Энтивио?

A: Official regulatory and clinical documents provide specific numerical percentages regarding the efficacy of the drug. These percentages detail the proportion of participants who achieved clinical response and remission in studies like GEMINI, compared to those receiving placebo.

Q: How is Энтивио generally eliminated or cleared from the body?

A: As a large monoclonal antibody, vedolizumab is generally eliminated from the body primarily through a non-specific elimination process. The drug is not metabolized via the Cytochrome P450 (CYP) enzyme system, which is responsible for processing many common medications.

Q: What should a patient do if they experience a common cold while on Энтивио?

A: The manufacturer’s patient guide indicates that individuals should notify their healthcare provider if they think they have an infection or if they experience symptoms like fever, persistent cough, or flu-like symptoms. This helps ensure proper evaluation of symptoms while on therapy.

Q: Can Энтивио affect a person's ability to get pregnant or affect male fertility?

A: Nonclinical toxicology studies, which involve animal models, were conducted to assess the effect on fertility for both males and females. These studies found no adverse effects on the fertility of rats at high doses. However, the product label contains separate cautionary information for use during human pregnancy.

Q: Can taking painkillers affect Энтивио treatment?

A: The official product information does not list common, non-prescription painkillers as a specific interaction. However, the product information suggests that patients share details of all medicines they are taking with their healthcare provider to manage overall risk.

Q: What types of over-the-counter medicines are known to have informational interactions with Энтивио?

A: No common over-the-counter (OTC) medicines are listed as specific formal interactions. Despite this, the product information notes that general caution is appropriate when using any concomitant medicine, due to the drug's effect on the immune system.

Q: Is Энтивио suitable for use during pregnancy, according to official information?

A: There are limited human data regarding the drug’s effects during pregnancy. Official guidance states that use during pregnancy is typically reserved for situations where the potential therapeutic benefit is determined to outweigh the potential risk to the mother and the developing fetus. A pregnancy exposure registry is available to help monitor outcomes.

Q: Why do some patients report feeling better quickly, while others take several months?

A: Clinical trial data recorded in official documents indicate a variability in the time it takes for the medicine to take effect. For instance, some Ulcerative Colitis patients achieved a clinical response as early as Week 6, while some Crohn's Disease patients took up to Week 14 to show evidence of therapeutic benefit.

Q: Does the Энтивио infusion typically require a hospital stay?

A: The intravenous infusion is administered by a healthcare professional in a controlled clinical setting, such as an infusion center or clinic. The professional must be prepared to manage any potential reactions, and the patient is required to be observed during and immediately after the infusion.

Q: Does the immune system generally return to its previous state after discontinuing Энтивио?

A: Due to its relatively long terminal elimination half-life of approximately 25.5 days, the drug is gradually cleared from the body over several weeks. As the drug is eliminated, the immune system is expected to return toward its pre-treatment baseline. Clinical trials have shown that retreatment after a treatment interruption was possible with efficacy being regained.

Q: Does the infusion process for Энтивио require any special preparation by the patient?

A: The official product information notes that for patients with a history of mild to moderate infusion-related reactions, pre-treatment with other medications may be considered by the healthcare provider. These may include an antihistamine, hydrocortisone, or paracetamol prior to the next scheduled infusion.

Q: Is Энтивио authorized for use in conditions other than Crohn's disease and Ulcerative Colitis?

A: While the main indications are Ulcerative Colitis and Crohn's Disease, some regulatory bodies, such as in the European Union, also authorize the use of the drug for chronic Pouchitis in adult patients.

Q: What is the risk classification for cancer associated with Энтивио based on regulatory documents?

A: The official product information includes a Warning and Precaution section on Malignancy. Data from long-term safety studies have shown that the number of malignancies observed in patients treated with Entyvio was similar to the expected rate for the general IBD patient population.

Q: What are the official guidelines regarding blood pressure monitoring during Энтивио infusions?

A: The product information states that appropriate monitoring and medical support must be available during the infusion. Patients are required to be observed during the infusion and for a period afterward, which includes the monitoring of vital signs such as blood pressure.

How to Store and Dispose of Entyvio (Vedolizumab)

Entyvio must be stored according to strict regulatory conditions to ensure stability. Both the intravenous (IV) infusion vial and the subcutaneous (SC) prefilled pen/syringe must be stored in a refrigerator at 2 C to 8 C (36 F to 46 F). The medication must be kept in its original packaging to ensure protection from light and must not be frozen.

Stability and Disposal

The SC prefilled pen/syringe can be stored out of the refrigerator at room temperature (up to 25 C) for a single period of up to seven days, after which it must be discarded. All Entyvio must be kept out of the sight and reach of children. Used SC pens/syringes must be disposed of immediately in an FDA-cleared sharps disposal container and must not be thrown into household trash.